EVOLUTION AT MERCK - INVENTING FOR LIFE

LENVIMA: ESTABLISHING AS TKI OF CHOICE MERCK INVENTING FOR LIFE and more ... • • . • Approved in markets worldwide in RCC, HCC and differentiated thyroid cancer Significant opportunity in China given prevalence of HCC in the market Strong commercial collaboration sets foundation for execution in many future indications 13 studies in combination with KEYTRUDA, including NSCLC, endometrial carcinoma and RCC Growth opportunities across multiple tumor types Hepatocellular carcinoma Endometrial carcinoma Lung cancer In collaboration with Eisai Thyroid cancer Renal cell carcinoma Frank Clyburn 22

View entire presentation